论文部分内容阅读
目的 :探讨 Fas配体 (Fas L)基因在急性髓性白血病中的表达及意义。方法 :应用反转录聚合酶链反应 (RT- PCR)检测 5 4例 AML 患者骨髓和健康志愿者骨髓中 Fas L 基因的表达。结果 :初发组 Fas L 相对基因表达水平为 0 .3343± 0 .0 32 4 ,复发组为 0 .32 4 1± 0 .0 5 4 3,均显著高于 (P<0 .0 1)正常对照组 (0 .0 716± 0 .0 0 95 ) ;初发组与复发组比较差异无显著性 (P>0 .0 5 )。 AML 患者治疗后有效者 Fas L 水平显著下降 ,无效者仍保持较高水平 ,完全缓解组与正常对照组比较无显著性差异。结论 :Fas L 水平的变化可作为监测治疗反应的一种手段
Objective: To investigate the expression and significance of Fas L gene in acute myeloid leukemia. Methods: The Fas L gene expression in the bone marrow and healthy volunteers of 54 AML patients was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Results: The relative gene expression level of Fas L in the primary group was 0.3343 ± 0.324 and in the recurrence group was 0.32 4 1 ± 0. 0543, which were significantly higher than those in the control group (P <0.01) The normal control group (0.0716 ± 0.0 955); no significant difference between the initial group and the recurrence group (P> 0.05). The levels of Fas L in patients with AML were significantly decreased after treatment, while those with ineffectiveness remained high. There was no significant difference between the complete remission group and the normal control group. Conclusion: The change of Fas L level can be used as a means to monitor response to treatment